News | Drug-Eluting Balloons | May 27, 2022

Medtronic Announces FDA Approval for IN.PACT 018 PTA Balloon Catheter

Built on the market-leading IN.PACT Admiral DCB technology, the IN.PACT 018 DCB is engineered to cross tight lesions and designed for better deliverability

Built on the market-leading IN.PACT Admiral DCB technology, the IN.PACT 018 DCB is engineered to cross tight lesions and designed for better deliverability

May 27, 2022 — Medtronic today announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, a drug coated balloon (DCB), indicated for the interventional treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries.

In the U.S. alone, 12 million people have PAD,1 a buildup of plaque in the walls of arteries, which limits or stops the flow of oxygen-rich blood to the limbs — and half of these individuals remain untreated, raising the risk of amputation.2

“The IN.PACT 018 DCB will allow physicians to better address challenging cases, such as those with narrow lesions or complex anatomies,” said Prakash Krishnan, MD, FACC, associate professor of medicine, cardiology, and radiology at the Icahn School of Medicine at Mount Sinai, who also serves on a scientific advisory board for Medtronic. “The available long-term data [from the IN.PACT Admiral studies] on its benefits gives physicians another effective treatment for PAD in complex anatomies.”   

The IN.PACT 018 DCB uses the same drug coating formulation and is built upon equivalent technology to the IN.PACT™ Admiral™ DCB, which is compatible with 0.035” guidewires. The IN.PACT 018 DCB is indicated for PTA of de novo, restenotic, or in-stent restenotic lesions with lengths up to 360 mm with vessel diameters of 4-7 mm. It is engineered to cross tight lesions, provide better deliverability§ and is compatible with 0.018" guidewires.

The IN.PACT 018 DCB will be the only commercially available DCB with a 200cm over-the-wire (OTW) catheter length, providing physicians the option to treat via femoral or radial access. This is in addition to the to the 130 cm OTW catheter length.

“Medtronic is committed to offering physicians a suite of products to treat patients with PAD. Based on feedback from our clinical community and the need for an 018” guidewire compatible DCB, Medtronic is excited to bring this technology to market in the U.S,” said David Moeller, president of the Peripheral Vascular Health Operating Unit at Medtronic. “The addition of the IN.PACT 018 DCB further reinforces Medtronic’s commitment to being the market leader in drug-coated balloons.”

With more than 3,500 patients enrolled in 21 clinical studies and 500,000+ patients treated worldwide†, the IN.PACT Admiral DCB has strong clinical outcomes, including: highest patency benefit through 3 years,3‡ having the lowest clinically driven target lesion revascularization (CD-TLR) through 5 years3, and most publications for a DCB*. Given the design similarities, the IN.PACT Clinical Program can be considered supportive for the IN.PACT 018 DCB.

The safety and effectiveness of the IN.PACT Admiral DCB (0.035 inch guidewire compatible), as established in the clinical studies (performed primarily via femoral access) can be considered supportive for the IN.PACT 018 DCB. The IN.PACT 018 DCB has not been evaluated in a clinical study.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers a broad range of innovative medical technology for the interventional and surgical treatment of cardiovascular and peripheral vascular disease. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

For more information:


1 Goodney PP, Tarulli M, Faerber AE, Schanzer A, Zwolak RM. Fifteen-year trends in lower limb amputation, revascularization, and preventive measures among Medicare patients. JAMA Surg. January 2015;150(1):84-86.|
2 Goodney PP, Travis LL, Nallamothu BK, et al. Variation in the use of lower extremity vascular procedures for critical limb ischemia. Circ Cardiovasc Qual Outcomes. January 2012;5(1):94-102.
3 Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. 5-year results from the IN.PACT SFA Trial. Circ Cardiovasc Interv. June 2019;12(6):e007702.

‡ Primary patency not assessed after three years.

†Based on sales units sold divided by units per procedure from approval through September 2019.

* Publications on file with Medtronic.

§ Data on file with Medtronic.

Compared to PTA  

Related Balloon Catheter Content:

IN.PACT AV Drug-Coated Balloon First and Only to Show Sustained and Superior Performance Compared to PTA Through 36 Months

Recent Developments in Drug-Coated Balloons

VIDEO: Overview of Drug-coated Balloons — Interview with Juan F. Granada, M.D.

New Angioplasty System Dilates Calcified and Fibrotic Vessels 

Balloon Catheter Comparison Chart (requires you to create login but it is free)

VIDEO: Demonstration of Intravascular Lithotripsy Breaking Up Calcium

Comparison Chart of Drug-eluting Balloons (requires login but is free to signup)

FDA Clears Coronary Intravascular Lithotripsy to Breakup Calcified Lesions With Sound Waves 

VIDEO: SCAI Prospective on Key Takeaways at TCT 2019 — Interview with Chandan Devireddy, M.D., including discussion of the LEVANT study results

Related Content

News | Angiography

January 31, 2024 — Coronary artery calcification is increasing in prevalence, leading to greater risks both during ...

Home January 31, 2024
Feature | Angiography | By Bhvita Jani

The world market for interventional X-ray and mobile C-arm equipment is forecast to reach over $4.9 billion by 2026 ...

Home November 09, 2022
News | Angiography
April 6, 2022 – According to ARRS’ American Journal of Roentgenology (AJR), the 3-T Dixon gradient-recalled echo (GRE) ...
Home April 06, 2022
News | Angiography

April 7, 2021 — Philips Healthcare announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Philips ...

Home April 07, 2021
Feature | Angiography | By Bhvita Jani

January 19, 2021 – With the postponement of non-essential elective surgeries and medical procedures in 2020 to conserve ...

Home January 19, 2021
News | Angiography

December 3, 2020 — GE Healthcare is introducing a new version of its robotic driven angiography system for image guided ...

Home December 01, 2020
Feature | Angiography | Dave Fornell, Editor

Philips is working on a prototype cath lab angiographic imaging system that might be able to replace the current X-ray ...

Home March 12, 2020
News | Angiography

February 12, 2020 — The University of Wisconsin (UW) Health’s University Hospital in Madison, Wis., recently became the ...

Home February 12, 2020
News | Angiography

October 9, 2019 — In the complex and fast-paced world of healthcare, customers face the challenge of staying up-to-date ...

Home October 09, 2019
Technology | Angiography

September 17, 2019 — The U.S. Food and Drug Administration (FDA) has cleared the Artis icono, a high-precision family of ...

Home September 17, 2019
Subscribe Now